(UroToday.com) The Realizing Potential Combination and Personalized Therapy educational session at the European Society of Medical Oncology’s (ESMO) 2021 congress included a presentation by Dr. Cristina Suarez discussing the future targets and combinations for metastatic RCC. These unique combinations include alternative proangiogenic pathways, immunotherapies/enhancing immune checkpoint inhibitors, metabolic pathways, and PARP inhibitors.